gc-1-compound has been researched along with Hypertriglyceridemia* in 1 studies
1 other study(ies) available for gc-1-compound and Hypertriglyceridemia
Article | Year |
---|---|
In vivo evaluation of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists: importance of liver selectivity in drug discovery.
We recently reported that the novel thyroid hormone receptor β (TRβ) selective agonists SKL-12846 and SKL-13784 reduce blood cholesterol levels without affecting thyroid-stimulating hormone (TSH) in cholesterol-fed rats. Our aim in this study was to elucidate what sets apart these SKL-compounds as TRβ agonists with no effect on TSH. To this end, we determined SKL-compounds pharmacokinetics and tissue distribution in normal rats and compared them to those of GC-1, a liver-selective TRβ agonist with concomitant effect on TSH. The present study explains why SKL-12846 and SKL-13784 have beneficial effects on lowering lipids without affecting heart rate and TSH production at the therapeutic dose in cholesterol-fed rats. In addition, we found that SKL-13784 shows no sign of escape phenomenon in fructose-fed rats. These results demonstrate the advantages of extremely high liver specificity to TRβ agonists. However, SKL-13784 has been found significantly to reduce endogenous T4 levels at doses lower than its lipid-lowering dose, which may raise concerns over this compound's ability to alter thyroid hormone metabolism in the liver. While the mechanism by which SKL-13784 reduces endogenous T4 levels is still unclear, our results would help design better liver-selective TRβ modulators. Topics: Acetates; Administration, Oral; Animals; Blood Glucose; Dose-Response Relationship, Drug; Drug Discovery; Heart Rate; Hypertriglyceridemia; Indoles; Injections, Intravenous; Lipids; Liver; Male; Malonates; Molecular Structure; Phenols; Rats, Sprague-Dawley; Structure-Activity Relationship; Thyroid Hormone Receptors beta; Thyroxine; Tissue Distribution; Triiodothyronine | 2014 |